Bioniz Therapeutics, Inc. logo

Bioniz Therapeutics, LLC.

Bioniz is a biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer.

Bioniz leverages its world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health (NIH), to develop a novel approach to selectively inhibit functionally redundant cytokines by blocking their unique binding interface with their shared receptor.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://bioniz.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
5 Mason St, Suite 275, CA 092618
Irvine
United States
Email
Contact Number
+1 949 273-6000

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/bioniz-llc” connections=”true” suffix=””]

Bioniz Therapeutics leverages its proprietary platform technology to develop novel peptides that target functionally redundant cytokines with targeted specificity.

In Aug 2016, Bioniz raised $13 Mn in its Series A funding co-led by Takeda Ventures Inc., and Dr. David Pyott, and also includes investments from Mr. Joe Kiani, and Cota Capital.